+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT)



The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT)



Experimental Hematology 23(14): 1667-1675



We assessed cytotoxic activity of large granular lymphocytes (LGLs) derived from 10 patients transplanted from molecular HLA-C mismatched (5) and matched (5) unrelated donors and compared it to the cytotoxic activity of 10 patients transplanted from HLA-identical siblings. In addition, we correlated clinical outcome with the level of molecular HLA-C disparity in a cohort of 22 patients who underwent unrelated BMT.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009612473

Download citation: RISBibTeXText

PMID: 8542963


Related references

The putative role of HLA-C recognition in graft versus host disease and graft rejection after unrelated bone marrow transplantation. Experimental Hematology 23(14): 1667-1675, 1995

The putative role of HLA-C recognition by natural killer cells in graft vs host disease and graft rejection post-bone marrow transplantation. Experimental Hematology 23(8): 744, 1995

XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplantation 13(5): 571-575, 1994

-Rejection of an allogeneic bone marrow graft following successful treatment of severe graft-versus-host disease (GVHD). Japanese Journal of Clinical Hematology 37(2): 134-138, 1996

T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival. Cancer Treatment and Research 50: 99, 1990

Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood 101(9): 3741-3748, 2003

The combination of tacrolimus, methotrexate, and methylprednisone completely prevents acute graft-versus-host disease but not chronic GVHD, in unrelated bone marrow transplantation. Blood 98(11 Part 2): 386b, 2001

Analysis of cytotoxic t cell precursor ctlp frequency and incidence of graft versus host disease gvhd for bone marrow transplantation with unrelated donors urds. Human Immunology (ABSTR ED): 104, 1990

Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice. Zhonghua Xue Ye Xue Za Zhi 33(2): 88-93, 2012

Clinical outcome by acute graft-versus host disease (GVHD) prophylaxis in patients underwent allogeneic bone marrow transplantation from unrelated donors: Nationwide survey in Japan. 2007

Graft versus host disease and graft rejection competing factors in bone marrow transplantation. Gale, R P And R Champlin (Ed ) Ucla (University Of California-Los Angeles) Symposia on Molecular And Cellular Biology New Series, Vol 53 Progress in Bone Marrow Transplantation; Fourth International Symposium, Keystone, Colorado, Usa, April 13-18, 1986 Xxxv+1012p Alan R Liss, Inc : New York, New York, Usa Illus 175-184, 1987

In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplantation 9(4): 255-261, 1992

Ultraviolet irradiation for the prevention of graft-versus-host disease and graft rejection in bone marrow transplantation. Bone Marrow Transplantation 14(4): 511-516, 1994

The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation. Leukemia Research 36(6): 699-703, 2012

Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92(12): 4581-4590, 1998